Orchid Chem to launch three new products in the US
18 July 2007
Chennai:
Orchid Chemicals & Pharmaceuticals plans to launch
three drugs in the US market this year. The three drugs
are: Cefepime and Cefdinir in the Cephalosporin range
and Tazobactum-Piperaillin in the penicillin range.
The company expects these drugs to fuel its growth in 2007-08. The addressable market for these three products in US is $1.5 billion (Rs6,000 crore).
In 2008-09, Orchid plans to launch antibiotic drugs in the ''carbopenam range. In addition, the company would begin marketing all the cephalosporin-based antibiotics in the European markets. The company has about a dozen products in that range.
Further, it would launch a cephalosporin-based veterinary injectible in the US.
The year 2009-10 would see "another step function jump" because of launch of another clutch of carbopenams and a range of non-antibiotic products in the US. This is significant because under a ''first to file'' law, Orchid would get a six-month market exclusivity for several of these products.
In 2009-10, Orchid would enter the lucrative Japanese market.